.

Previous Requests April 2018

3 April 2018

835

All CCGs

 Under the Freedom of Information Act, we would like to obtain the following information please:

1) The number of female cancer-related fertility preservation cycles funded in your CCG over the last 2 years from 1st January 2015 to 31st December 2017.

2) Could you please state your criteria which you use to make a decision on funding.

3) Does your CCG restrict funding for fertility preservation based on:
a. Age range
b. BMI
c. Previous children

4) Do you still require fertility centres to fill in an exceptional funding application form?

5) How long does it take for your CCG to process funding for fertility preservation?

6) What is the duration of storage that is funded by your CCG?

Click here for response
 3 April 2018 836 - 838                

All CCGs

 I would like to make enquiries about your Lymphoedema Service in the treatment of Lipoedema, specifically:

1. How many patients have received compression tights and/or stockings funded by the CCG in the management of Lipoedema in the last 12 months?
2. How many patients have received Manual Lymphatic Drainage massage (MLD) funded by the CCG for the management of Lipoedema in the last 12 months?
3. How many patients have received funded surgical intervention for Lipoedema funded by the CCG in the last 12 months?

Click here for response 
 4 April 2018

 839

NDCCG

 Under the Freedom of Information Act, please could you provide me, within the prescribed 20 working days, with the following information:

Copies of all documents, correspondence, meeting notes, telephone calls and emails between 1st June 2017 – 31st July 2017 in which Homeopathy has been discussed:

1) Between North Derbyshire CCG and NHS England
2) Between North Derbyshire CCG and The Good Thinking Society (or their lawyer)

Click here for response
 5 April 2018

 840

All CCGs

 Please provide answers to the questions below including answer for the previous three financial years (2015-16, 2016-17, 2017-18) and any known information (for example, planned spending) for the year 2018-19. If you cannot provide information for the full three-year period, the most recent information you have would be appreciated.

1. Do you employ a mental health lead?

2. Spending on mental health (total)
a. What was the total amount (£) allocated to mental health trusts?
b. What was the total amount of money spent (£) on mental health services by your CCG?

3. Adult mental health: Acute hospital liaison
a. Do you commission A&E and Ward liaison teams to operate 24/7? Are such liaison teams universally included in contracts for the provision of acute hospital services?

4. Adult mental health: Crisis and acute care and suicide prevention
a. Do you commission a crisis resolution home treatment (CRHT) as an alternative to acute in-patient admission? Does this service operate 24/7?
b. Response times

5. Children’s and young people’s (CYP) mental health
a. Do you involve CYP and parents/carers in commissioning and service design for CYP?
b. Do you commission specialist treatment for CYP with eating disorders?
c. What is the proportion of CYP with eating disorders seen within 1 week (urgent) and 4 weeks (routine)?

6. Perinatal mental health
a. Do you commission specialist perinatal mental health services? If so, what was the total amount (£) and total amount spent on perinatal mental health services?
b. Do you have a strategy for providing perinatal mental health services?

7. Mental health of older persons
a. Do you commission tailored, community based, physical or other activity programmes for older persons?

Click here for response
 6 April 2018

 841

NDCCG

Following Ref. 827:
Could you send me details of the splits of consultant referrals in the following :

Type – the hospital dept concerned e.g. ENT, Cardiology etc.
Age ranges too -perhaps child / adult / senior or age ranges
                

Click here for response

Click here for spreadsheet          

10 April 2018 

842 / 846 / 851

SDCCG 

Copies of all documents, correspondence, meeting notes, telephone calls and emails between

1 August 2017 – 30 September 2017

1 October 2017 - 30 November 2017

1 December 2017 - 31 January 2018

in which Homeopathy has been discussed:
1) Between the CCG and NHS England
2) Between the CCG and The Good Thinking Society (or their lawyer)

Click here for response Aug-Sept 

Click here for response Oct-Nov         

Click here for response Dec-Jan

 10 April 2018

 843

SDCCG

This request is asking for information during 2016/17 and 2017/18. If you have recently commissioned a MSK Triage service, please provide the date the service commenced:
If possible please show the activity pre and post service commencement.

1) What was your total MSK spend and how many contacts were provided in:
Year Spend Contacts
2016/17  
2017/18  

2) What percentage of contacts were for physiotherapy?
Year Physiotherapy contacts % of all contacts
2016/17  
2017/18  

3) What is covered within your MSK triage service:
Area Covered Yes/No Comments
Physiotherapy  
Pain Management  
Orthopaedics  
Spinal/Back  
Rheumatology  


4) How many referrals did the MSK Triage service receive in:
Year Referrals received
2016/17 
2017/18 

5) Regarding referrals to MSK Triage, what percentage of referrals are:

 % of referrals
Retained by the MSK service 
Returned to GP 
Referred on to Secondary care 

6) What is your average waiting time for:
a) Physiotherapy
b) MSK Triage
If it is not possible to separate, please provide average waiting times for MSK Triage

Click here for response
 844

11 April 2018

All CCGs 

 
Q1. Please state the total number of Individual Funding Requests (IFRs) for knee surgery that the CCG received in each of the following years:
a) 2017-18
b) 2016-17
c) 2015-16

Q2. Please state the number of Individual Funding Requests (IFRs) for knee surgery that the CCG approved for funding in each of the three years listed in Q1.

Q3.  Please state the total number of Individual Funding Requests (IFRs) for hip surgery that the CCG received in each of the three years listed in Q1.

Q4. Please state the number of Individual Funding Requests (IFRs) for hip surgery that the CCG approved for funding in each of the three years listed in Q1.

Q5. Please provide a current list of all services and treatments the CCG commissions which require an Individual Funding Request (IFR) to be made. Please list any services or treatments that have been added to this list in the past 12 months.

Click here for response

Click here for PLCV policy

 845

12 April 2018

All CCGs

 
Amount spent (£) by each of the CCGs you are responsible for on GPSoC (GP Systems of Choice) Lot 2
•        By software provider (if possible)
•        Per year
•        Over the past 3 (calendar or NHS financial) years

 

Information not held. Redirected to North East CSU.  
 847

16 April 2018

All CCGs 

 1.       Please tell me whether the CCG has updated its cataract referral guidelines - stating the criteria for referring patients for cataracts - in the last 12 months?
 
2.       Please attach a link to the latest cataract referral guidelines.
 
3.       Please tell me whether the guidelines apply to a group of several CCGs – and if so which CCGs.

Click here for response
 848

17 April 2018

SDCCG 

 
1. Please provide the following information for the people responsible for the following HR functions
1a. Overall HR
1b. HR/Workforce Planning

2. For the following financial years, please provide the following information
"2a. What is the organisations total gross pay costs
(all expenditure on staff)"
"2b. What is the organisations total pay costs on your permanent workforce
(staff that hold permanent contracts only)"
"2c. How much did the organisation spend on contingent (non-permanent) or temporary workers
(this includes any temporary or contract workers such as agency workers, casual workers, temps, self-employed workers / contractors, inc. PSCs, umbrella companies, and all types of short and long term contractors) "

3. For the following financial years, please provide the following information, providing the figures as the number of employees & full time equivalents (FTE)
How many permanent workers did the organisation employ:
3a. Number of Employees
3b. Full Time Equivalent (FTE)
"On average, how many contingent (non-permanent) or temporary workers has the organisation engaged with:
(this includes any temporary or contract workers such as agency workers, casual workers, temps, self-employed workers / contractors, inc. PSCs, umbrella companies, and all types of short and long term contractors) "
3c. Number of Employees
3d. Full Time Equivalent (FTE)

4. Please list the software the organisation uses for the following HR functions
4a. HR
"4b. Payroll
(if the organisation uses multiple payroll software for different workers/payroll frequencies ie. substantive, agency/weekly, monthly payroll - please list all)"
4c. Recruitment
4d. HR/Workforce Analytics
4e. Other employee/HR related systems for tracking or planning


5. Please state which Enterprise Resource Planning (ERP) software the organisation utilises e.g Oracle, SAP, PeopleSoft, Workday
6. Does the organisation have a HR data warehouse?

Click here for response

Click here for attachment

 849

18 April 2018

All CCGs 

 We are writing to enquire under the Freedom of Information Act, what your eligibility criteria are for breast cancer patients who are wanting to undergo fertility preservation (for example cryopreservation), provided there is adequate time and their oncology allows.
 
More specifically;
• Is there an upper age limit (female/male)?
• Is there a limit on whether the patient already has children?
• Are there any restrictions, specifically smoking status or body mass index?
•  What fertility options are offered?  For example, embryo cryopreservation and/or oocyte cryopreservation?
• Is there a time limit for storage?
• How many IVF cycles or embryo transfers are covered?
 
In addition, what information on breast cancer patients undergoing fertility preservation do you currently collate, for example, numbers referred each year, numbers undergoing treatment and successful pregnancies each year, and is this data available for us to access?
 
Click here for response
 850

19 April 2018

All CCGs 

1. Do you have local clinical pathways or standard operating procedures (SOPs) for the use of MabThera? If so are you able to share these? For instance, is one cycle of MabThera intravenous (IV) always used before initiating the patients on MabThera subcutaneous (SC) in oncology indications?

2. Number of patients treated* using MabThera subcutaneous versus MabThera intravenous in oncology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to.

3. Total number of patients treated* with MabThera (intravenous and subcutaneous) vs Rixathon vs Truxima in oncology and rheumatology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to.

4. Do you have local clinical pathways or standard operating procedures (SOPs) for the initiation of new patient treatment regimens? If so are you able to share these?

5. Specifically, are new patients directly prescribed biosimilar rituximab (i.e. Truxima or Rixathon) instead of MabThera?

6. Are existing patients being switched from MabThera intravenous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?

7. Are any existing patients being switched from MabThera subcutaneous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?

8. Number of patients treated* using rituximab biosimilars (Truxima and Rixathon) instead of MabThera (intravenous and subcutaneous) between 2016-2018, if only partial data is available please indicate the timeframe the data refers to.

9. As an organisation, are you aware of any financial savings made by using biosimilar rituximab (i.e. Truxima or Rixathon) vs MabThera between 2017-2018, if only partial data is available please indicate the timeframe the data refers to and the methods used to calculate the financial savings. 
   
10. Please provide information on the current contracts for Truxima, Rixathon, MabThera intravenous (IV) or subcutaneous (SC):
Drug Contract value (£)* Volume of contract (number of vials) Is price tiered by volume?
(Yes/No) Length of contract Renewal frequency Services included
Date of contract initiation Date of contract expiry  Yes/No Which services
(e.g. biosimilar education, patient support program…)
           

*if the total contract value is not available, please provide the price range for each drug

11. Related to question 10, if contracts are tiered by volume, could you please provide the thresholds for each tier and what is the price percentage difference between tiers?


 

Click here for response
 852

20 April 2018

NDCCG 

 I would like to know the following for the past year year please

The number and percentage of cancellations at the eye clinic

Ditto for any patients cancelled more than once and any more than twice

Is there a system to avoid same patients being cancelled

Do any patients whose appointment is cancelled go to the end of the queue

 

Please click for response
 853 23/04/2018 

 I would like to request the following information regarding supported living services for adults with learning disabilities (LD,) mental health (MH) and Autism Spectrum Disorders (ASD). Please provide answers on the attached and accompanying spreadsheet, and where ever possible, please provide separate out for each category of LD, MH, and ASD .

1. Please could you supply the name, email address and telephone number of the commissioner with responsibility for placements in supported living.

2. Please provide the number of supported living services the CCG currently contract with, for adults with LD, MH and ASD. Where possible, please separate out for each category of LD, MH, and ASD, as shown in the attached spreadsheet.

3. Please provide a list of the names of those supported living services mentioned in Q2, with the name of the provider that provides the care in them. Where possible, please separate out for each category of LD, MH, and ASD.

4. Please provide the highest hourly rate the CCG pays to providers of supported living services for adults with LD, MH and ASD.

5. Please provide the lowest hourly rate the CCG pays to providers of supported living services for adults with LD, MH and ASD.

6. Please provide the average hourly rate the CCG pays to providers of supported living services for adults with LD, MH and ASD.

7. Please provide the average weekly fee the CCG pays to providers of supported living services for adults with LD, MH and ASD.

8. Please provide the total number of adults funded by the CCG in supported living services for adults with LD, MH and ASD. Where possible, please separate out for each category of LD, MH, and ASD, as shown in the attached spreadsheet.

9. Of the total number of adults funded by the CCG in supported living services for adults with LD, MH and ASD, (q.8) please provide the number that are male and the number that are female. Where possible, please separate out for each category of LD, MH, and ASD, as shown in the attached spreadsheet. 

10. Of the total number of adults funded by the CCG in supported living services for adults with LD, MH and ASD, (q.8) please provide the number that were placed ‘in area’ and the number that were placed ‘out of area'. By 'out of area', I mean people that are funded by the CCG, but placed outside the CCG boundaries.

Please click for response
 854

23 April 2018

All CCGs 

1. The number of adults currently receiving NHS Continuing Healthcare.

2. The number of adults currently receiving NHS Continuing Healthcare who are currently in receipt of a Personal Health Budget.

3. The number of adults not currently receiving NHS Continuing Healthcare who are currently in receipt of a Personal Health Budget.

4. The number of adults currently receiving NHS Continuing Healthcare who have requested Personal Health Budgets and are awaiting a decision on their request.

5. The number of adults not currently receiving NHS Continuing Healthcare who have requested Personal Health Budgets and are awaiting a decision on their request.

6. The total number of adults who received Personal Health Budgets during 2015/16 (for CHC patients).

7. The total value of Personal Health Budgets awarded to adults during 2015/16 for that financial year (for CHC patients).

8. The total number of adults who received Personal Health Budgets during 2016/17 (for CHC patients).

9. The total value of Personal Health Budgets awarded to adults during 2016/17 for that financial year (for CHC patients).

10. The total number of adults who received Personal Health Budgets during 2017/18 (for CHC patients).

11. The total value of Personal Health Budgets awarded to adults during 2017/18 for that financial year (for CHC patients).              

Click here for response

Click here for attachment

 855

24 April 2018

All CCGs 

 1. Please can you confirm that ‘Purchase of healthcare from non-NHS bodies’ includes any healthcare purchased from ISTCs (independent sector treatment centres), private providers (e.g. Bupa, Virgin Care), social enterprises, GP provider companies, as well as other company structures?


2. Please can you provide a breakdown of the contracts, including the sum of money spent on each contract, that make up the ‘Purchase of healthcare from non-NHS bodies’ category in the annual accounts for each CCG that you deal with for the financial year 2017-18? In the breakdown, please provide the organisation name and type of service provided for each contract.

Please click for response
 856

24 April 2018

NDCCG 

 I would like to request the information about the following points around the CCG's decisions with patient care and its structure.


• What criteria does the CCG use to select which inhalers should be prescribed for Asthma and COPD?
• How does the CCG compare the cost-effectiveness , efficacy, safety and patient usability of different inhalers when selecting which COPD and Asthma inhalers should be included on its local guidance?
• Over the past three years, has the CCG introduced a planned programme of care which resulted in the medicines optimisation team, contractors or GP practices proactively reviewing patients and aligning their COPD and/or Asthma inhalers to alternative options?
• Please list the alternative asthma and COPD inhalers that were introduced by the CCGs medicines optimisation team, contractors or GP practices during any planned programme of care that proactively reviewed the use of asthma and/or COPD inhalers over the past 3 years .
• Over the past three years, has the CCG used a QIPP scheme to introduce a planned programme of care which resulted in the medicines optimisation team, contractors or GP practices proactively reviewing patients and aligning their COPD and/or Asthma inhalers to alternative options?
• Please list the alternative asthma and COPD inhalers that were introduced by the CCGs medicines optimisation team, contractors or GP practices when using a QIPP scheme to introduce a planned programme of care that proactively reviewed the use of asthma and/ or COPD inhalers over the past 3 years?

I would also like to make a request for the full name, contact number and contact email for the following roles listed below within your CCG;
Roles:
Chief Executive Officer
Chief Financial Officer
Medicines Management Lead

Please click for response
 857

25 April 2018

All CCGs 

 1.    The number of people deemed ineligible for continuing healthcare for each financial year since 2011/12 and the reasons these applications were turned down.

2.    The number of Continuing Healthcare (CHC) appeals since 2011/12, broken down by financial year.

3.    The number of successful CHC appeals for each financial year since 2011/12 and the reason these appeals were successful.

 

Please click for response

Please click for attachment

Last modified: 16/05/2018